TMOMEDIUM SIGNALFINANCIAL10-K

TMO reported solid revenue growth while significantly increasing debt levels, accompanied by a substantial rise in interest expense.

The company appears to be executing a capital-intensive growth strategy, evidenced by the meaningful increase in total debt to $39.2B and corresponding rise in interest expense. While revenue growth of 14.5% demonstrates strong operational performance, investors should monitor whether the incremental debt deployment generates adequate returns to justify the higher financial leverage and interest burden.

Comparing 2026-02-26 vs 2025-02-20View on EDGAR →
FINANCIAL ANALYSIS

TMO delivered strong top-line growth with revenue expanding 14.5% to $20.9B, while total assets grew 13.4% to $110.3B reflecting business expansion. However, the company substantially increased its debt position by 26.1% to $39.2B, resulting in interest expense that grew notably to $1.4B. The reduction in share buybacks to $3.0B suggests management is prioritizing debt-funded growth investments over shareholder returns, creating a more leveraged capital structure that warrants close monitoring.

FINANCIAL STATEMENT CHANGES
Interest Expense
P&L
+89.4%
$726.0M→$1.4B

Interest expense surged 89.4% — significant debt increase or rising rates materially impacting earnings.

Current Assets
Balance Sheet
+29.7%
$22.1B→$28.7B

Current assets grew 29.7% — improving short-term liquidity or inventory/receivables build.

Total Debt
Balance Sheet
+26.1%
$31.1B→$39.2B

Debt rose 26.1% — additional borrowing for investment or operations; monitor coverage ratios.

Share Buybacks
Cash Flow
-25%
$4.0B→$3.0B

Buyback activity reduced 25% — capital being redeployed elsewhere or cash conservation underway.

Revenue
P&L
+14.5%
$18.3B→$20.9B

Revenue growing 14.5% — solid top-line momentum, watch margins for quality of growth.

Current Liabilities
Balance Sheet
+13.9%
$13.3B→$15.2B

Current liabilities rose 13.9% — increased short-term obligations, watch current ratio.

Total Assets
Balance Sheet
+13.4%
$97.3B→$110.3B

Asset base grew 13.4% — expansion through organic growth, acquisitions, or capital deployment.

LANGUAGE CHANGES
NEW — 2026-02-26
PRIOR — 2025-02-20
ADDED
As of January 31, 2026, the Registrant had 371,484,244 shares of Common Stock outstanding.
Forward-looking statements are based on current expectations and assumptions that are subject to risks and uncertainties, and are often identified by words such as expects, anticipates, intends, plans, believes, seeks, estimates, may, will, should, or similar expressions or words with similar meanings.
Any statements contained herein that are not statements of historical fact should be considered forward-looking statements.
Important risks and uncertainties that could cause such differences are detailed under the heading, Risk Factors in Part I, Item 1A.
While the company may elect to update forward-looking statements in the future, it specifically disclaims any obligation to do so, in the event of new information, future developments, or otherwise, except as required by law.
Life Sciences Solutions includes three primary businesses: biosciences, genetic sciences, and bioproduction.
Our bioproduction business provides solutions for both the production of biologics and industrial manufacturing, and offers a comprehensive portfolio of premium solutions and services focused on upstream cell culture, downstream purification, analytics for detection, quantitation, filtration and separation of process/product impurities, and a suite of single-use solutions spanning the biologics workflow.
Our R D efforts focus on developing new technologies, enhancing the performance and usability of existing offerings, and expanding the applications for which our products are used.
These activities include internal development programs, initiatives leveraging licensed or acquired technologies, and collaborations with leading research institutions around the world.
Our R D programs are aligned with the needs of each major business and are critical to maintaining our competitive position and supporting our long-term growth strategy.
REMOVED
As of February 1, 2025, the Registrant had 377,261,182 shares of Common Stock outstanding.
Without limiting the foregoing, the words believes, anticipates, plans, expects, seeks, estimates, and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements are accompanied by such words.
While the company may elect to update forward-looking statements in the future, it specifically disclaims any obligation to do so, even if the company s estimates change, and readers should not rely on those forward-looking statements as representing the company s views as of any date subsequent to the date of the filing of this report.
A number of important factors could cause the results of the company to differ materially from those indicated by such forward-looking statements, including those detailed under the heading, Risk Factors in Part I, Item 1A.
Life Sciences Solutions includes three primary businesses Biosciences, Genetic Sciences, and BioProduction.
Our bioproduction business supports developers and manufacturers of biological-based therapeutics and vaccines with a portfolio of premium solutions and services focused on upstream cell culture, downstream purification, analytics for detection and quantitation of process/product impurities, and a suite of single-use solutions spanning the biologics workflow.
We also enter into license agreements with others to grant and/or receive rights to intellectual property rights.
Solely for convenience, we may refer to trademarks in this Annual Report on Form 10-K without the and symbols.
To the extent other trademarks appear in this Annual Report on Form 10-K, they are the property of their respective owners.
Our success primarily depends on the following factors: technical performance and advances in technology that result in new products and improved price/performance ratios; product differentiation, availability and reliability; the depth of our capabilities; our reputation among customers as a quality provider of products and services; customer service and support; active research and application-development programs; and relative prices of our products and services.
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →